rapcabtagene autoleucel (YTB323) Clinical Trials
2 recruitingBiologic
Phase 12Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled18 locationsNCT06617793
Recruiting
Phase 1Phase 2
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Progressive Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled17 locationsNCT06675864